Increased likelihood of experiencing prolonged neutralizing antibody response seen for those with vaccine-associated symptoms, prior SARS-CoV-2 infection<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, March 20, 2023 (HealthDay News) — Messenger RNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination leads to transient antibody response, with more sustained response for mRNA-1273 than BNT162b2, for those experiencing vaccine-associated symptoms, and for those with prior SARS-CoV-2 infection, according to a study published online Feb. 4 in Vaccines<\/em>.<\/p>\n Kevin D. Dieckhaus, M.D., from UConn Health in Farmington, Connecticut, and colleagues examined the dynamics between vaccine products, prior SARS-CoV-2 illness, and incidence of vaccine-associated adverse reactions on antibody decay over time in health care workers at a university medical center. A cohort of 296 health care workers received standard two-dose vaccination with BNT162b2 or mRNA-1273 and were assessed after two, six, and nine months. Participants were classified according to antibody decay curve into steep and gentle decliners.<\/p>\n The researchers found that compared with vaccination with BNT162b2, vaccination with mRNA-1273 led to more sustained antibody responses. The likelihood of experiencing a more prolonged neutralizing antibody response was increased among individuals experiencing vaccine-associated symptoms. Individuals with prior SARS-CoV-2 infection were more likely to experience vaccination-associated symptoms after first vaccination and were also more likely to have a more blunted decay of antibodies.<\/p>\n “Prior infection with COVID meant you were more likely to have a sustained immune response,” Dieckhaus said in a statement. “It definitely set your immune system to respond in a more vigorous way to the vaccination.”<\/p>\n